AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2673620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum chewing
Number of subjects: 10
Study 2673620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine during adenosine infusion
Number of subjects: 10
Study 2673620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of nicotine and adenosine
Number of subjects: 10
Study 239109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.58M (7%) THAM over 30 seconds
Number of subjects: 19
Study 239109 — intervention group
Group type: EXPERIMENTAL
Intervention: molar bicarbonate over 30 seconds
Number of subjects: 19
Study 239109 — intervention group
Group type: EXPERIMENTAL
Intervention: molar bicarbonate over 2 minutes
Number of subjects: 19
Study 239109 — intervention group
Group type: EXPERIMENTAL
Intervention: molar bicarbonate over 5 minutes
Number of subjects: 19
Study 30378278 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional (3D) quiz application
Number of subjects: 0
Study 30378278 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching with extracted/model teeth
Number of subjects: 0
Study 28236862 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mgkg‐1 sugammadex (Group S)
Number of subjects: 98
Study 28236862 — intervention group
Group type: COMPARATOR
Intervention: 50μgkg‐1 neostigmine plus 0.2mgkg‐1 atropine (Group N)
Number of subjects: 98
Study 28236862 — intervention group
Group type: COMPARATOR
Intervention: Group N
Number of subjects: 98
Study 28236862 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S
Number of subjects: 98
Study 24787302 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-sugar-tong splint (DSTS)
Number of subjects: 71
Study 24787302 — intervention group
Group type: COMPARATOR
Intervention: Long-arm cast (LAC)
Number of subjects: 71
Study 23186950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 141
Study 23186950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 22145828 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity intervention (30 minutes of individualized cognitive-behavioral intervention and a self-help manual)
Number of subjects: 0
Study 22145828 — intervention group
Group type: COMPARATOR
Intervention: Low intensity intervention (brief advice for 5 minutes and a short leaflet)
Number of subjects: 0
Study 22145828 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at six months postpartum
Number of subjects: 0
Study 22145828 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants' birth weight, gestational age, and health-related complications during pregnancy
Number of subjects: 0
Study 19249415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0
Study 19249415 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17250777 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg imipramine
Number of subjects: 20
Study 17250777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15236439 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (Polpharma)
Number of subjects: 18
Study 15236439 — intervention group
Group type: COMPARATOR
Intervention: Lioresal (Novartis)
Number of subjects: 18
Study 11210404 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1200 mg/day (changed to 600 mg/day) for Days 8 to 21 with zidovudine 100 mg, five times/day.
Number of subjects: 12
Study 11210404 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1200 mg/day for Days 8 to 21 with dideoxyinosine 200 mg twice daily.
Number of subjects: 12
Study 11210404 — intervention group
Group type: COMPARATOR
Intervention: Placebo equivalent to azithromycin for Days 8 to 21 with dideoxyinosine 200 mg twice daily.
Number of subjects: 12
Study 9624643 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 8
Study 9624643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8986931 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium diet
Number of subjects: 6
Study 8986931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet
Number of subjects: 6
Study 8986931 — intervention group
Group type: COMPARATOR
Intervention: Non-sodium-sensitive essential hypertension (Control group)
Number of subjects: 6
Study 1981014 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with estrogenic recruitment (low doses of diethylstilbesterol)
Number of subjects: 0
Study 1981014 — intervention group
Group type: COMPARATOR
Intervention: Conventional polychemotherapy
Number of subjects: 0
Study 1981014 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 0
Study 7033568 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal tunnel technique for prevention of reflux
Number of subjects: 0
Study 7033568 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 0
Study 7033568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31618672 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinguished cue during training
Number of subjects: 0
Study 31618672 — intervention group
Group type: COMPARATOR
Intervention: Non-extinguished cue
Number of subjects: 0
Study 27798397 — intervention group
Group type: EXPERIMENTAL
Intervention: PP‐ACT
Number of subjects: 104
Study 27798397 — intervention group
Group type: COMPARATOR
Intervention: C‐ACT
Number of subjects: 104
Study 25304836 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose antibiotic regimen (n = 103)
Number of subjects: 205
Study 25304836 — intervention group
Group type: COMPARATOR
Intervention: Multidose antibiotic regimen (n = 102)
Number of subjects: 205
Study 25359150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pateclizumab 360 mg
Number of subjects: 214
Study 25359150 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 214
Study 25359150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 22594649 — intervention group
Group type: EXPERIMENTAL
Intervention: KRTE only (KO)
Number of subjects: 44
Study 22594649 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture only (AO)
Number of subjects: 44
Study 22594649 — intervention group
Group type: EXPERIMENTAL
Intervention: KRTE and acupuncture combined (KA)
Number of subjects: 44
Study 22594649 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (WL)
Number of subjects: 44
Study 20413058 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily ADPREM
Number of subjects: 38
Study 20413058 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily CRM
Number of subjects: 38
Study 18614424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (100 mg)
Number of subjects: 0
Study 18614424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 0
Study 18614424 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study 15749968 — intervention group
Group type: EXPERIMENTAL
Intervention: Going Places Program
Number of subjects: 1320
Study 11918715 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10 (10 microg per kg body weight; n = 7)
Number of subjects: 17
Study 11918715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 17
Study 11918715 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10
Number of subjects: 17
Study 11918715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 10509984 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless xenograft (SX)
Number of subjects: 139
Study 10509984 — intervention group
Group type: COMPARATOR
Intervention: Cryopreserved aortic or pulmonary homografts (HX)
Number of subjects: 139
Study 8621019 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate (100 mg/day)
Number of subjects: 13
Study 8621019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1591738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (40 mg)
Number of subjects: 12
Study 1591738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6389273 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid group A (7.5 ml, 103.5 mmol antacid/day)
Number of subjects: 107
Study 6389273 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid group B (15 ml, 207 mmol antacid/day)
Number of subjects: 107
Study 6389273 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid group C (30 ml, 414 mmol antacid/day)
Number of subjects: 107
Study 6389273 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (15 ml)
Number of subjects: 107
Study 31697724 — intervention group
Group type: EXPERIMENTAL
Intervention: GP care (WHO mhGAP training)
Number of subjects: 294
Study 31697724 — intervention group
Group type: COMPARATOR
Intervention: Clinical Psychologists care (co-location framework)
Number of subjects: 294
Study 29661516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Number of subjects: 25
Study 29661516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 25443420 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized skin care regimen 1
Number of subjects: 280
Study 25443420 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized skin care regimen 2
Number of subjects: 280
Study 25443420 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study 23380429 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg meloxicam orodispersible tablet (ODT)
Number of subjects: 28
Study 21512162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1817
Study 21512162 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1817
Study 19477503 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-length graduated compression stockings (GCS)
Number of subjects: 2518
Study 19477503 — intervention group
Group type: COMPARATOR
Intervention: Avoidance of graduated compression stockings (GCS)
Number of subjects: 2518
Study 17715080 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous catheter drainage (PCD)
Number of subjects: 60
Study 17715080 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous needle aspiration
Number of subjects: 60
Study 17715080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 15208492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-isotope gated myocardial perfusion SPECT (GMPS) with 201Tl injected at rest and 99mTc sestamibi (99mTc-MIBI) injected at peak stress
Number of subjects: 236
Study 15208492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-isotope gated myocardial perfusion SPECT (GMPS)
Number of subjects: 236
Study 11433048 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV)
Number of subjects: 64
Study 11433048 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 64
Study 11433048 — intervention group
Group type: EXPERIMENTAL
Intervention: SNIPPV (in infants with poor lung function)
Number of subjects: 64
Study 11433048 — intervention group
Group type: COMPARATOR
Intervention: NCPAP (in infants with poor lung function)
Number of subjects: 64
Study 11433048 — intervention group
Group type: EXPERIMENTAL
Intervention: SNIPPV
Number of subjects: 64
Study 8448744 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant recombinant IFN‐alpha‐2a (rIFN‐alpha 2a) (9 x 10(6) IU subcutaneously, three times per week for a maximum of 12 months)
Number of subjects: 270
Study 8448744 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 270
Study 3777684 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal fluid loading (Group I, n = 20)
Number of subjects: 54
Study 3777684 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion (Group II, n = 17)
Number of subjects: 54
Study 3777684 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamine infusion (dopamine or dobutamine, Group III, n = 17)
Number of subjects: 54
Study 29626145 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 306
Study 29626145 — intervention group
Group type: COMPARATOR
Intervention: Flat insoles
Number of subjects: 306
Study 26925704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex (up to 108 mg THC/100 mg CBD)
Number of subjects: 9
Study 26925704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 26925704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex or placebo
Number of subjects: 9
Study 26925704 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-titrated doses of Sativex
Number of subjects: 9
Study 24373290 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand washing
Number of subjects: 0
Study 24373290 — intervention group
Group type: COMPARATOR
Intervention: Control households
Number of subjects: 0
Study 24077196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral parasagittal interlaminar epidural steroid injection (PIL)
Number of subjects: 106
Study 24077196 — intervention group
Group type: COMPARATOR
Intervention: Midline interlaminar epidural steroid injection (MIL)
Number of subjects: 106
Study 24077196 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant pressure paresthesia during LESI
Number of subjects: 106
Study 20509997 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg once daily for 48 weeks)
Number of subjects: 125
Study 20509997 — intervention group
Group type: COMPARATOR
Intervention: Adefovir (10 mg once daily for 48 weeks)
Number of subjects: 125
Study 18204337 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 99
Study 18204337 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 99
Study 18204337 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 99
Study 18204337 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 99
Study 16131645 — intervention group
Group type: EXPERIMENTAL
Intervention: Male-to-female transgender persons who are HIV positive
Number of subjects: 59
Study 16131645 — intervention group
Group type: COMPARATOR
Intervention: Nontransgender control subjects who are HIV positive
Number of subjects: 59
Study 12682421 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (400 IU dL-a-tocopherol daily)
Number of subjects: 128
Study 12682421 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 128
Study 10750771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiotomy suction during CPB to cardiotomy reservoir (CR)
Number of subjects: 20
Study 10750771 — intervention group
Group type: COMPARATOR
Intervention: Cell saving device (CS) during CPB
Number of subjects: 20
Study 10750771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saving device (CS) reservoir
Number of subjects: 20
Study 10750771 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood from the wound
Number of subjects: 20
Study 9010746 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-releasing vaginal ring (2 mg/3 months) and oral progestin for 7 days every month
Number of subjects: 56
Study 9010746 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estrogen (50 micrograms/day) with a levonorgestrel-releasing IUD (20 micrograms/day)
Number of subjects: 56
Study 1446959 — intervention group
Group type: EXPERIMENTAL
Intervention: Timonil 600 retard from Desitin Arzneimittel GmbH
Number of subjects: 14
Study 1446959 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (R)
Number of subjects: 14
Study 3792350 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 27
Study 3792350 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide and 5 mg amiloride hydrochloride (combination therapy)
Number of subjects: 27
Study 3792350 — intervention group
Group type: COMPARATOR
Intervention: Diuretics (50 mg hydrochlorothiazide and 5 mg amiloride hydrochloride)
Number of subjects: 27
Study 30340474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 160
Study 30340474 — intervention group
Group type: COMPARATOR
Intervention: Schema Therapy (ST)
Number of subjects: 160
Study 30340474 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT and ST
Number of subjects: 160
Study 26829599 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Number of subjects: 23
Study 26829599 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Number of subjects: 23
Study 26829599 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MMF and EC-MPS
Number of subjects: 23
Study 24072551 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope laryngoscope
Number of subjects: 100
Study 24072551 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 100
Study 24072551 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of anaesthesia
Number of subjects: 100
Study 24261229 — intervention group
Group type: EXPERIMENTAL
Intervention: BP < or = 140/90 mm Hg
Number of subjects: 66
Study 24261229 — intervention group
Group type: EXPERIMENTAL
Intervention: BP > or = 160/100 mm Hg
Number of subjects: 66
Study 24261229 — intervention group
Group type: COMPARATOR
Intervention: Control group (apparently healthy individuals)
Number of subjects: 66
Study 20533911 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory guidance intervention applied during pregnancy and at 6 and 12 months of age.
Number of subjects: 649
Study 20533911 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 649
Study 19249923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (PCA) with fentanyl 0.5 microg/kg every 15 minutes (maximum 4 doses/hour)
Number of subjects: 64
Study 19249923 — intervention group
Group type: COMPARATOR
Intervention: PRN intravenous fentanyl 25-50 microg every 30 minutes
Number of subjects: 64
Study 19249923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (PCA)
Number of subjects: 64
Study 19249923 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study 16441618 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate gel Flaminal (test)
Number of subjects: 20
Study 16441618 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid gel Intrasite (control)
Number of subjects: 20
Study 15531005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg once daily
Number of subjects: 86
Study 15531005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 10886120 — intervention group
Group type: EXPERIMENTAL
Intervention: GR205171 25 mg i.v.
Number of subjects: 16
Study 10886120 — intervention group
Group type: EXPERIMENTAL
Intervention: GR205171 25 mg i.v. + ondansetron 8 mg i.v.
Number of subjects: 16
Study 10886120 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine hydrobromide 0.6 mg orally (positive control)
Number of subjects: 16
Study 10886120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9082268 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm anesthetic solution (37 degrees C)
Number of subjects: 70
Study 9082268 — intervention group
Group type: COMPARATOR
Intervention: Cold anesthetic solution (20 degrees C)
Number of subjects: 70
Study 8452165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for 10 days
Number of subjects: 587
Study 8452165 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin 400 mg twice daily for 10 days
Number of subjects: 587
Study 8452165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 587
Study 8452165 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 587
Study 8452165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin and Norfloxacin
Number of subjects: 587
Study 3512783 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without bleomycin
Number of subjects: 307
Study 3512783 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy with immunotherapy (BCG, levamisole, or both)
Number of subjects: 307
Study 3512783 — intervention group
Group type: COMPARATOR
Intervention: Initial full-dose therapy for patients aged 65 or older
Number of subjects: 307
Study 3512783 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial dose reduction of 50% for patients aged 65 or older
Number of subjects: 307
Study 29322313 — intervention group
Group type: EXPERIMENTAL
Intervention: Empty PEEK cages
Number of subjects: 45
Study 29322313 — intervention group
Group type: COMPARATOR
Intervention: PEEK cages filled with β‐tricalcium phosphate
Number of subjects: 45
Study 27716478 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab 6 mg/kg once every 2 weeks
Number of subjects: 999
Study 27716478 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (400 mg/m2 followed by 250 mg/m2 weekly)
Number of subjects: 999
Study 24781960 — intervention group
Group type: EXPERIMENTAL
Intervention: JADE + PEARL (n=312)
Number of subjects: 628
Study 24781960 — intervention group
Group type: COMPARATOR
Intervention: JADE (n=316)
Number of subjects: 628
Study 24781960 — intervention group
Group type: EXPERIMENTAL
Intervention: JADE + PEARL
Number of subjects: 628
Study 24781960 — intervention group
Group type: COMPARATOR
Intervention: JADE
Number of subjects: 628
Study 21660669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (BWL) treatment for 30 min every morning during chemotherapy
Number of subjects: 39
Study 21660669 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (DRL) treatment for 30 min every morning during chemotherapy
Number of subjects: 39
Study 20351591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle tape
Number of subjects: 22
Study 18298356 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training group
Number of subjects: 65
Study 18298356 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity training group
Number of subjects: 65